Christopher Paul Simms - 09 Dec 2025 Form 3 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Chief Commercial Officer
Signature: /s/ Scott Bizily as Attorney-in-Fact for Christopher Paul Simms
Issuer symbol: FDMT
Transactions as of: 09 Dec 2025
Net transactions value: $0
Form type: 3
Filing time: 19 Dec 2025, 16:12:30 UTC
Previous filing: 13 Jul 2023
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Simms Christopher Paul	Chief Commercial Officer	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE	/s/ Scott Bizily as Attorney-in-Fact for Christopher Paul Simms	19 Dec 2025	0001877012

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	FDMT	Stock Option (Right to Buy)							09 Dec 2025	Common Stock	300,000	$9.38	Direct	F1
holding	FDMT	Stock Option (Right to Buy)							09 Dec 2025	Common Stock	32,403	$4.14	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to the stock option vest on the first anniversary measured from September 11, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F2	The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Content

25% of the shares subject to the stock option vest on the first anniversary measured from September 11, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Remarks:

Chief Commercial Officer